Related Experiment Video
Updated: Apr 29, 2026

Use of a High-throughput In Vitro Microfluidic System to Develop Oral Multi-species Biofilms
Published on: December 1, 2014
Microfluidic-derived montmorillonite composite microparticles for oral codelivery of probiotic biofilm and
Zhonglin Fang1, Xinyuan Yang1, Luoran Shang1
1Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, and the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.
Abstract:
Oral delivery of probiotics has shown promising effects in modulating the gut microbiota and treating ulcerative colitis (UC). However, the therapeutic efficacy is restricted by gastrointestinal assaults, poor mucosal adhesion, and single therapeutic modality. Here, we developed acid-resistant, gut-environment-responsive composite microparticles based on microfluidic electrospray for the oral codelivery of probiotic [Lactobacillus acidophilus (LA)] biofilm and postbiotics (indole-3-propionic acid). Montmorillonite was selected for supporting biofilm formation due to its cation-exchange capability and clearly defined biosafety. The montmorillonite-LA biofilm was effectively protected by the microparticles and markedly improved the intestinal retention. Upon oral administration, the composite microparticles notably alleviated colitis in mice, including reducing the inflammatory response, improving intestinal barrier function, and modulating the gut microbiota. Consequently, the composite microparticles show high potential for enhancing probiotic delivery efficacy and present a promising strategy for UC treatment.
Insights
This study developed advanced microparticles for oral delivery of probiotics and postbiotics to treat ulcerative colitis (UC). The novel formulation improved gut retention and effectively reduced inflammation in a mouse model.
Area of Science:
- Gastroenterology and Microbiology
- Biomaterials Science
- Drug Delivery Systems
Background:
- Oral probiotics show potential for ulcerative colitis (UC) but face challenges like degradation and poor adhesion.
- Current treatments for UC are limited by efficacy and side effects.
- Developing effective delivery systems is crucial for enhancing probiotic therapy.
Purpose of the Study:
- To create acid-resistant, gut-responsive composite microparticles for co-delivery of probiotic Lactobacillus acidophilus (LA) biofilm and postbiotics.
- To enhance the stability, mucosal adhesion, and therapeutic efficacy of oral probiotics for UC treatment.
- To investigate the potential of these microparticles in alleviating colitis.
Main Methods:
- Utilized microfluidic electrospray to fabricate composite microparticles encapsulating montmorillonite-supported LA biofilm and indole-3-propionic acid.
- Assessed microparticle acid resistance and gut-environment responsiveness.
- Evaluated the therapeutic effects in a mouse model of colitis, measuring inflammatory markers, intestinal barrier function, and gut microbiota composition.
Main Results:
- Developed stable, acid-resistant microparticles that improved intestinal retention of LA biofilm.
- Demonstrated significant alleviation of colitis in mice, including reduced inflammation and improved intestinal barrier function.
- Showed modulation of the gut microbiota composition following administration of the composite microparticles.
Conclusions:
- Composite microparticles offer a promising strategy for enhanced oral delivery of probiotics and postbiotics.
- This novel formulation effectively alleviates colitis in a preclinical model.
- The developed microparticle system holds high potential for improving probiotic therapeutic efficacy in UC treatment.
Related Concept Videos
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Biofilms
Microbial Corrosion
Probiotics
The Oral Microbiota
Development of the Oral Microbiota

